NeuroDerm Ltd. (Nasdaq: NDRM) announced that it has initiated enrollment of Parkinson's disease (PD) patients in a Phase III efficacy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE